(S)-2-({1-[5-((S)-1-t-Butoxycarbonyl-2-phenyl-ethylcarbamoyl)-2H-pyrazol-3-yl]-methanoyl}-amino)-3-phenyl-propionic acid t-butyl ester | 233585-02-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-({1-[5-((S)-1-t-Butoxycarbonyl-2-phenyl-ethylcarbamoyl)-2H-pyrazol-3-yl]-methanoyl}-amino)-3-phenyl-propionic acid t-butyl ester
• 英文别名: tert-butyl (2S)-2-[[3-[[(2S)-1-[(2-methylpropan-2-yl)oxy]-1-oxo-3-phenylpropan-2-yl]carbamoyl]-1H-pyrazole-5-carbonyl]amino]-3-phenylpropanoate
• CAS: 233585-02-9
• 化学式: C₃₁H₃₈N₄O₆
• 分子量: 562.666
• InChiKey: QGQNRNVAHYTUTM-DQEYMECFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  41
• 可旋转键数：
  14
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  140
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (S)-2-({1-[5-((S)-1-t-Butoxycarbonyl-2-phenyl-ethylcarbamoyl)-2H-pyrazol-3-yl]-methanoyl}-amino)-3-phenyl-propionic acid t-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 (2S,2'S)-2,2'-((1H-pyrazole-3,5-dicarbonyl)bis(azanediyl))bis(3-phenylpropanoic acid)
  参考文献：
  名称：

  Heterocyclic HIV-1 Protease Inhibitors

  摘要：

  A series of simple heterocyclic HIV-1 protease inhibitors were developed on the basis of size, shape, and electronic complementarity to the active site of the enzyme, The C-2-symmetric heterocycles do not contain a transition-state isostere nor are they active site directed irreversible inhibitors; thus, they represent the success of a new design strategy. The first generation heterocycles inhibit the protease in the micromolar range, whereas control compounds show no bioactivity at the same concentrations.

  DOI：

  10.1021/ol990586y
• 作为产物：
  描述：

  3,5-吡唑二甲酸 、 L-苯丙氨酸叔丁酯盐酸盐 在 1-羟基苯并三唑一水物 、 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以8%的产率得到(S)-2-({1-[5-((S)-1-t-Butoxycarbonyl-2-phenyl-ethylcarbamoyl)-2H-pyrazol-3-yl]-methanoyl}-amino)-3-phenyl-propionic acid t-butyl ester
  参考文献：
  名称：

  Heterocyclic HIV-1 Protease Inhibitors

  摘要：

  A series of simple heterocyclic HIV-1 protease inhibitors were developed on the basis of size, shape, and electronic complementarity to the active site of the enzyme, The C-2-symmetric heterocycles do not contain a transition-state isostere nor are they active site directed irreversible inhibitors; thus, they represent the success of a new design strategy. The first generation heterocycles inhibit the protease in the micromolar range, whereas control compounds show no bioactivity at the same concentrations.

  DOI：

  10.1021/ol990586y

文献信息

• Heterocyclic HIV-1 Protease Inhibitors
  作者：Paul W. Baures

  DOI：10.1021/ol990586y

  日期：1999.7.1

  A series of simple heterocyclic HIV-1 protease inhibitors were developed on the basis of size, shape, and electronic complementarity to the active site of the enzyme, The C-2-symmetric heterocycles do not contain a transition-state isostere nor are they active site directed irreversible inhibitors; thus, they represent the success of a new design strategy. The first generation heterocycles inhibit the protease in the micromolar range, whereas control compounds show no bioactivity at the same concentrations.